-
公开(公告)号:US20050240430A1
公开(公告)日:2005-10-27
申请号:US11114736
申请日:2005-04-26
申请人: Jason Baum
发明人: Jason Baum
CPC分类号: G08B7/06 , G06Q90/205 , G08B5/36
摘要: Emergency situations can be difficult to manage in any business enterprise. Embodiments of the invention are directed to systems and methods that allow a business enterprise, such as a petrochemical plant, hospital, or high rise building, to manage information regarding an emergency situation. This management system is preferably capable of providing customized evacuation reports to various individuals throughout the business enterprise. Such customized evacuation reports may be useful, for example, in a petrochemical plant when weather conditions change rapidly rendering previous evacuation plans hazardous. Further, these customized reports also may be useful in predicting the location of various individuals within the business enterprise, which may be a difficult task in an emergency situation.
摘要翻译: 紧急情况在任何企业都难以管理。 本发明的实施例涉及允许诸如石油化工厂,医院或高层建筑物的商业企业管理关于紧急情况的信息的系统和方法。 该管理系统优选地能够为整个商业企业中的各个个体提供定制的撤离报告。 这种定制的撤离报告可能是有用的,例如,当天气条件迅速变化时,在石油化工厂,以前的疏散计划是危险的。 此外,这些定制报告也可能有助于预测企业内各个人的位置,这在紧急情况下可能是一项困难的任务。
-
公开(公告)号:US08476409B2
公开(公告)日:2013-07-02
申请号:US13451135
申请日:2012-04-19
申请人: Jason Baum , Bryan Johnson , Alexey Alexandrovich Lugovskoy , Lihui Xu , Neeraj Kohli , Jonathan Basil Fitzgerald , Sharlene Adams
发明人: Jason Baum , Bryan Johnson , Alexey Alexandrovich Lugovskoy , Lihui Xu , Neeraj Kohli , Jonathan Basil Fitzgerald , Sharlene Adams
CPC分类号: C07K16/2863 , A61K2039/505 , C07K16/2869 , C07K16/30 , C07K16/32 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
摘要翻译: 提供可用作抗肿瘤剂并且特异性结合人IGF-1R和人ErbB3的双特异性抗体。 示例性的抗体通过IGF-1R和ErbB3之一或两者抑制信号转导。
-
3.
公开(公告)号:US20120269812A1
公开(公告)日:2012-10-25
申请号:US13451135
申请日:2012-04-19
申请人: Jason BAUM , Bryan JOHNSON , Alexey Alexandrovich LUGOVSKOY , Lihui XU , Neeraj KOHLI , Jonathan Basil FITZGERALD , Sharlene ADAMS
发明人: Jason BAUM , Bryan JOHNSON , Alexey Alexandrovich LUGOVSKOY , Lihui XU , Neeraj KOHLI , Jonathan Basil FITZGERALD , Sharlene ADAMS
IPC分类号: C07K16/46 , A61P35/00 , C07H21/04 , A61K39/395
CPC分类号: C07K16/2863 , A61K2039/505 , C07K16/2869 , C07K16/30 , C07K16/32 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.
摘要翻译: 本文提供了可用作抗肿瘤剂并且特异性结合人IGF-1R和人ErbB3的新型单特异性和双特异性抗体。 示例性的抗体通过IGF-1R和ErbB3之一或两者抑制信号转导。 示例性的多价蛋白质包含至少一个抗IGF-1R结合位点和至少一个抗ErbB3结合位点。 在某些实施方案中,结合位点可以通过免疫球蛋白恒定区连接。 还提供了新的抗ErbB3和抗IGF-1R抗体(例如,单克隆抗体)。
-
-